TABLE 4.
Asthma control outcomes in asthma patients aged 6–17 years in Sweden, Norway and Finland in 2018
| Sweden | Norway | Finland | ||||
| Mild-to-moderate | Severe | Mild-to-moderate | Severe | Mild-to-moderate | Severe | |
| Patients | 58 647 | 264 | 26 602 | 256 | 32 003 | 86 |
| Recurrent exacerbations#(≥2 exacerbations) | 1969 (3) | 98 (37) | 111 (0) | 36 (14) | 244 (8) | 32 (37) |
| Asthma-related ED visit | 2762 (5) | 26 (10) | 706 (2) | <5 | ||
| Asthma-related hospital admission | 308 (0.5) | 11 (4) | 234 (1) | <5 | ||
| High SABA use | 12 634 (22) | 125 (47) | 5915 (22) | 121 (47) | 3600 (11) | 18 (21) |
| Uncontrolled asthma¶ | 14 091 (24) | 186 (70) | 5998 (23) | 142 (55) | 3902 (12) | 46 (53) |
| Antibiotics | 8205 (14) | 70 (27) | 3337 (13) | 81 (32) | 10 643 (33) | 40 (47) |
| Hospital attendance with pneumonia | 375 (0.6) | 12 (5) | 275 (1) | <5 | ||
Data are presented as n or n (%). ED: emergency department; SABA: short-acting β-agonist. #: defined as either a dispensation with burst oral corticosteroid (OCS) (Anatomical Therapeutic Chemical Classification code H02AB), or an asthma-related ED visit in 2018, or as an asthma-related hospital admission; ¶: defined as at least two OCS dispensations and/or asthma-related ED visits and/or at least one asthma-related admission and/or high SABA use (of ≥600 doses (puffs)).